|
Newly established pharma firm Bayer Schering Pharma Indonesia
said Monday it expected to become the leader of the multinational
pharmaceutical sector here by the end of the year.
The new firm is the result of the acquisition of Schering Pharma AG by
Bayer Pharma AG.
"Having acquired Schering Pharma globally, the company, now named Bayer
Schering Pharma Indonesia, will become the leading multinational
pharmaceutical firm here," Angel-Michael Evangelista, the country
division head of Bayer Schering Pharma Indonesia, told a press
conference in Jakarta
Germany-based Bayer Pharma AG acquired Schering Pharma AG, also
Germany-based, last October for more than 17 billion euros (US$22.8
billion).
PT Bayer Indonesia finalized all the legal procedures here on April 1
to combine its operations with those of PT Schering Indonesia.
In Indonesia prior to the merger, Bayer Indonesia was eighth in terms
of assets and PT Schering Indonesia 14th among the multinational
pharmaceutical companies operating here.
The new company, Bayer Schering Pharma Indonesia, has now jumped to top
five afterwards, and it plans to become No. 1 by the end of 2007.
According to an issue of local biweekly business magazine SWA published
last June, domestic pharmaceutical firm Kalbe Farma led the domestic
market in 2005, followed by United States-based Pfizer in second place
and local firm Tempo Scan Pacific in third.
After the takeover, Bayer Schering Pharma Indonesia's board of
management now consists of six former executives of Bayer Indonesia and
five of Schering Indonesia, said Evangelista.
The new company employs 106,000 workers in total, and no redundancies
have resulted from the combining of the two operations.
Bayer Schering Pharma's head of specialty care, Hadi Syarif, said that
the new company currently had a some 7 percent domestic market share.
For his part, Evangelista said that the mew company would dominate the
market for specialty care products.
"In an effort to achieve our target, we will focus more on specialty
care products, which will account for 70 percent of Bayer Schering
Pharma Indonesia's total sales," he said.
"We will also concentrate on cardiovascular and metabolic, women's
healthcare and oncology products," he explained.
The company operates five plants -- in Cibubur, Pasar Rebo and
Cimanggis in Jakarta, Anyer in Banten and Surabaya in East Java. They
are confined to packaging operations as almost all of the company's
products are imported from Germany.
Bayer Schering Pharma's total global sales amounted to 7 billion euros
last year.
|
